n | ||
Age (years), mean (SD); median (IQR) | 79.1 (9.4); 80.5 (10) | 394 |
Females, % | 61.9 | 394 |
Ischaemic aetiology, % | 35.5 | 372 |
LVEF >40%, % | 70.5 | 370 |
Comorbidities | ||
Hypertension, % | 87.8 | 394 |
AF, % | 51.3 | 394 |
Diabetes mellitus, % | 48.7 | 394 |
Chronic pulmonary disease, % | 28.7 | 394 |
Dementia, % | 22.6 | 394 |
Sleep disorder/hypoventilation syndrome, % | 20.6 | 394 |
Need for caregiving, % | 20.3 | 394 |
Stroke, % | 18.5 | 394 |
Peripheral arterial disease, % | 11.9 | 394 |
Active cancer, % | 6.6 | 394 |
Admission | ||
SBP (mm Hg), mean (SD); median (IQR) | 140.5 (29.0); 137.0 (38) | 385 |
First NT-proBNP (pg/mL), mean (SD); median (IQR) | 5931.3 (10062.8); 2485.5 (5279.8) | 336 |
RDW (%), mean (SD); median (IQR) | 15.4 (2.0); 14.9 (2.2) | 393 |
Htc (%), mean (SD); median (IQR) | 37.9 (3.6); 38.1 (8.4) | 394 |
Hgb (g/dL), mean (SD); median (IQR) | 12.0 (2.1); 12.1 (2.8) | 394 |
Platelet count (x103/µL), mean (SD); median (IQR) | 223.4 (88.2); 208.0 (93) | 394 |
PDW (%), mean (SD); median (IQR) | 13.7 (2.6); 13.5 (3.0) | 385 |
Discharge | ||
ACEi/ARB, % | 52.2 | 393 |
Beta-blocker, % | 52.9 | 393 |
MRA, % | 17.3 | 393 |
Oral anticoagulant, % | 30.0 | 393 |
PCr, mean (SD); median (IQR) | 1.3 (0.6); 1.1 (0.6) | 388 |
PUr, mean (SD); median (IQR) | 67.5 (34.8); 59.0 (41.5) | 389 |
PK+, mean (SD); median (IQR) | 4.3 (0.5); 4.3 (0.7) | 390 |
PNa+, mean (SD); median (IQR) | 139.2 (5.3); 140.0 (5) | 389 |
ACEi, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; Hgb, haemoglobin; Htc, haematocrit; LVEF, left ventricle ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal-pro-B type natriuretic peptide; PCr, plasma creatinine; PDW, platelet distribution width; PK+, plasma potassium; PNa+, plasma sodium; PUr, plasma urea; RDW, red cell distribution width; SBP, systolic blood pressure.